Prophylactic Tocilizumab in CRS Management

This chapter discusses the role of prophylactic tocilizumab in addressing cytokine release syndrome (CRS) in patients undergoing bispecific therapies. The speakers evaluate the effectiveness and practicality of using TOSI versus simpler interventions for managing fevers, while also considering cost, patient safety, and the complexities of outpatient care. They highlight the need for tailored approaches and improved communication strategies in managing CRS and the implications of treatment protocols.